| Language | English |
|---|---|
| Pages | S708 |
| Number of pages | 1 |
| Journal | European Journal of Cancer |
| Volume | 51 |
| Issue number | Supplement 3 |
| DOIs | |
| Publication status | Published - Sep 2015 |
| Externally published | Yes |
| Event | European Cancer Congress - Vienna, Austria Duration: 25 Sep 2015 → 29 Sep 2015 |
Cite this
}
CheckMate 025 : a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC). / Sharma, P.; Escudier, B.; McDermott, D. F.; George, S.; Hammers, H. J.; Srinivas, S.; Tykodi, S. S.; Sosman, J. A.; Procopio, G.; Plimack, E. R.; Castellano, D.; Gurney, H.; Donskov, F.; Bono, P.; Wagstaff, J.; Gauler, T. C.; Ueda, T.; Xu, L. A.; Waxman, I. M.; Motzer, R. J.
In: European Journal of Cancer, Vol. 51, No. Supplement 3, 09.2015, p. S708.Research output: Contribution to journal › Meeting abstract › Research
TY - JOUR
T1 - CheckMate 025
T2 - European Journal of Cancer
AU - Sharma, P.
AU - Escudier, B.
AU - McDermott, D. F.
AU - George, S.
AU - Hammers, H. J.
AU - Srinivas, S.
AU - Tykodi, S. S.
AU - Sosman, J. A.
AU - Procopio, G.
AU - Plimack, E. R.
AU - Castellano, D.
AU - Gurney, H.
AU - Donskov, F.
AU - Bono, P.
AU - Wagstaff, J.
AU - Gauler, T. C.
AU - Ueda, T.
AU - Xu, L. A.
AU - Waxman, I. M.
AU - Motzer, R. J.
PY - 2015/9
Y1 - 2015/9
U2 - 10.1016/S0959-8049(16)31926-8
DO - 10.1016/S0959-8049(16)31926-8
M3 - Meeting abstract
VL - 51
SP - S708
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - Supplement 3
ER -